TD Waterhouse Canada
ARCT icon

TD Waterhouse Canada’s Arcturus Therapeutics ARCT Stock Holding History

TD Waterhouse Canada’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-85
Closed -$1.37K – 1709
2022
Q2 		$1.37K Hold
85
– – ﹤0.01% 1587
2022
Q1 		$2.45K Hold
85
– – ﹤0.01% 1568
2021
Q4 		$3.27K Buy
+85
New +$3.46K ﹤0.01% 1514

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

TD Waterhouse Canada's ARCT Position: Q3 2022 in Review

TD Waterhouse Canada sold out of Arcturus Therapeutics (ARCT) in Q3 2022, closing a stake of 85 shares — an estimated $1.37K sold.

TD Waterhouse Canada first reported a position in ARCT in Q4 2021 and held it in 3 quarters. The position peaked at $3.27K in Q4 2021. 116 funds tracked by Wall St. Rank hold ARCT as of Q3 2022.

  • TD Waterhouse Canada reported no remaining Arcturus Therapeutics position as of Q3 2022 after selling out during the quarter.
  • TD Waterhouse Canada sold 85 Arcturus Therapeutics shares in Q3 2022, an estimated $1.37K.
  • TD Waterhouse Canada first reported a position in Arcturus Therapeutics in Q4 2021 and held it in 3 quarters.
  • TD Waterhouse Canada's Arcturus Therapeutics position peaked at $3.27K in Q4 2021.
  • 116 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2022.

Based on TD Waterhouse Canada's 13F filing for Q3 2022, filed 13 Nov 2023.